Sort   by:  
 Page size 
ProteomicsABPP of Ibrutinib Resistance in B Cell Malignancies
Ibrutinib,a novel Bruton'styrosine kinase inhibitor, demonstrated high response rates in B-cell lymphomas but a growing number of ibrutinib treated patients relapse with resistance, fulminant progression and accelerated mortality. Using chemical proteomics and a high-throughput ex vivo assay in a re...
ORGANISM(S): Homo sapiens (Human) 
2018-10-26 | PXD005734 | Pride
Ibrutinib Activity-based protein profiling B-cell cancers Lc-ms/ms 
ProteomicsBCL2 amplicon loss and super-enhancer remodeling drives ABT-199 resistance
Drug-tolerant “persister” tumor cells underlie the emergence of drug-resistant clones contribute to relapse and disease progression; thus, identifying actionable targets that disable persisters and mitigate relapse are a high priority need. Although the BCL2-targeting agent venetoclax (ABT-199) has ...
ORGANISM(S): Homo sapiens (Human) 
2020-05-26 | PXD010193 | Pride
Abpp Lymphoma Persister Apoptosis 
ProteomicsAllocryptopine alleviates IBD through modulating gut microbiota and inhibiting Cx3cl1-Cx3cr1 axis/NF-κB/apoptosis in DSS-induced mice
To explore the anti-inflammatory bowel disease (IBD) ability of allocryptiine based on label-free quantitative proteomics
ORGANISM(S): Mus Musculus 
2022-12-12 | PXD038736 |
ProteomicsProteomics comparison of protein changes in H1299 cell before and after resistance to cdk4/6 inhibitors
This is the raw proteomics data of H1299 cell before and after resistance to cdk4/6 inhibitors
ORGANISM(S): Homo Sapiens 
PXD042216 |
UnknownEvaluation of the therapeutic effects of QuickOpt optimization in Chinese patients with chronic heart failure treated by cardiac resynchronization.
Not available
S-EPMC5844885 | biostudies-literature
Sort   by:  
 Page size